FMR LLC and Abigail P. Johnson filed an amended beneficial ownership statement with the SEC on November 5, 2026, disclosing a combined holding of 11,136,649.17 shares of Xenon Pharmaceuticals Inc. common stock as of September 30, 2026, representing 11.5% of the class.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC and Abigail P. Johnson each report beneficial ownership of 11,136,649.17 shares of Xenon Pharmaceuticals Inc. common stock.
  • Percent of class: The reported holdings represent 11.5% of Xenon Pharmaceuticals Inc.'s outstanding common stock.
  • Sole voting power (FMR LLC): FMR LLC reports sole voting power over 11,128,597.00 shares, with no shared voting power.
  • Sole dispositive power: Both FMR LLC and Abigail P. Johnson report sole dispositive power over 11,136,649.17 shares, with no shared dispositive power.
  • Event date: The date of the event requiring this filing is stated as September 30, 2026.
  • Amendment number: This filing is Amendment No. 9 to a prior beneficial ownership statement covering Xenon Pharmaceuticals Inc. common stock (CUSIP 98420N105).

FMR LLC and Abigail P. Johnson Disclose Position in Xenon Pharmaceuticals

According to the filing, FMR LLC, a Delaware-organized holding company headquartered at 245 Summer Street, Boston, Massachusetts 02210, together with Abigail P. Johnson, a United States citizen, reported an aggregate beneficial ownership of 11,136,649.17 shares of common stock in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage pharmaceutical company based in Burnaby, British Columbia, Canada. The filing is classified as Amendment No. 9 and was triggered by an event dated September 30, 2026.

The filing indicates that FMR LLC holds sole voting power over 11,128,597.00 shares and sole dispositive power over 11,136,649.17 shares, with no shared voting or dispositive power reported. Abigail P. Johnson, identified as a reporting person in a separate cover-page entry, reports sole dispositive power over the same 11,136,649.17 shares, but no sole or shared voting power. FMR LLC is classified as a parent holding company (type "HC") and Abigail P. Johnson is classified as an individual (type "IN") under the applicable SEC instructions.

The filing also discloses, in response to Item 6, that one or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, Xenon Pharmaceuticals Inc. common stock, but that no single other person's interest exceeds five percent of the total outstanding common stock. The filing was signed by Stephanie J. Brown on November 4, 2026, acting under duly authorized powers of attorney on behalf of both FMR LLC and Abigail P. Johnson.

What Was Disclosed

FMR LLC and Abigail P. Johnson filed Amendment No. 9 to their beneficial ownership statement, reporting aggregate holdings of 11,136,649.17 shares, equal to 11.5% of Xenon Pharmaceuticals Inc. common stock, based on a September 30, 2026 triggering event.